A six minute walking test (6MWT) derived index (O2-GAP) predicts mortality in IPF Source: International Congress 2015 – IPF: clinical aspects II Year: 2015
Differences in FVC decline by extent of emphysema in patients with combined pulmonary fibrosis and emphysema (CPFE) syndrome Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015
Diffusing capacity for carbon monoxide (DLco) may predict appearance of pulmonary hypertension in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013
The right ventricle (RV) in systemic sclerosis-associated pulmonary arterial hypertension (SSCPH) vs idiopathic pulmonary arterial hypertension (IPH): higher inflammatory status, no increase in interstitial fibrosis Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009
The effect of pulmonary rehabilitation on exercise tolerance pulmonary function dyspnea and quality of life in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –The best posters in pulmonary rehabilitation Year: 2013
A therapeutic arteriovenous fistula not only improves exercise tolerance, but also BODE index in patients with severe COPD Source: Annual Congress 2007 - Treatment and care of COPD Year: 2007
What is the role of hypoxaemia, 6-minute walk test, diffusion capacity, pulmonary arterial hypertension in diffuse interstitial lung diseases? Source: Annual Congress 2009 - Clinical aspects of diffuse parenchymal lung disease Year: 2009
The body-mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index in Filipino patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2005; 26: Suppl. 49, 57s Year: 2005
A new multidimensional model for predicting mortality in COPD: body mass index and FEV1 quotient/MRC dyspnoea score (SID) Source: Annual Congress 2006 - COPD – the challenges for primary care Year: 2006
The role of secondary pulmonary hypertension (SPH) in the limited exercise tolerance of patients with interstitial lung disease (ILD) Source: Eur Respir J 2005; 26: Suppl. 49, 560s Year: 2005
Challenges in idiopathic pulmonary fibrosis trials: the point on end-points Source: Eur Respir Rev 2011; 20: 195-200 Year: 2011
Clinical predictors of pulmonary hypertension in sarcoidosis Source: Eur Respir J 2008; 32: 296-302 Year: 2008
Pulmonary hypertension in idiopathic pulmonary fibrosis: correlation to pulmonary function and exercise parameters Source: Eur Respir J 2007; 30: Suppl. 51, 607s Year: 2007
Abnormal pulmonary arterial remodelling in patients with combined pulmonary fibrosis emphysema (CPFE) and idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2011 - Clinical approach of diffuse parenchymal lung disease Year: 2011
Relationship of cardiopulmonary exercise testing (CPET) and lung function in idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2007; 30: Suppl. 51, 120s Year: 2007
Pulmonary rehabilitation (PR) exercise tolerance improvement: Differences between interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2013 –Exercise, physiotherapy techniques and assessment in different chronic conditions Year: 2013
Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013
Pulmonary arterial hypertension in combined pulmonary emphysema and fibrosis Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy Year: 2005
Pulmonary vascular response patterns during exercise in interstitial lung disease (ILD) Source: International Congress 2014 – Mechanisms of exercise limitation in disease Year: 2014